gener
reason report
gx proair delay lower ep ep impact could
bottom line friday market close report
expect receiv complet respons letter fda
abbrevi new drug applic anda gx proair
longer expect launch gx proair achiev
expect ep benefit product
appear yet receiv actual point
visibl defici identifi fda long
issu might take address know right
fda issu still believ abl
get gx proair approv eventu given fda continu commit
approv gener re-emphas presid trump
blueprint lower drug price releas friday turn
around fda request soon delay month could still
see captur larg part ep contribut
gx proair contribut model expect news
neg impact investor contempl
extent delay beyond news also posit ep
impact brand proair manufactur teva estim
ep impact gx proair
come year delay opportun
larger two key launch year investor like wait
sidelin get better visibl compani longer-
term strateg vision unveil later year and/or addit growth
long road approv got longer much longer
remain unknown recal first paragraph iv p-iv
filer teva proair reach settlement permit
limit quantiti licenc launch gener begin decemb
unlimit launch quantiti june howev perrigo
receiv around need year resubmit
applic around second disclos
earn call time manag point addit
clinic studi request march appear perrigo
abl respond issu although littl visibl
type issu highlight latest base
recent regulatori histori wherein receiv
late time receipt approv would
year could see scenario could still turn around fda
request within month approv lupin
p-iv filer gx proair submit substanti
complet applic fda novemb reach
settlement teva believ could permit launch
time-frame lupin action date around
given difficulti get product goal line possibl
approv could delay even past current expect
assum launch earli could still launch gx
proair ahead lupin long tail product could
meaning revenu contributor compani howev news
expect yet rais uncertainti around time
pleas refer page import disclosur price chart analyst certif
launch look ad visibl detail better
estim long re-submiss process might take
ami fadia certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
use weight averag ev/ebitda multipl deriv pt roughli line con
ebitda appli multipl arriv pt
risk valuat
limit rx-to-otc switch opportun and/or delay new rx over-the-counter product launch could result share
trade lower expect initi drive busi may success anticip lead
share perform better expect
ebitda ev/ebitda multipl drive teva lower view pt
risk valuat
higher-than-expect number new gx launch lower-than-expect number competitor copaxon key
brand product austedo fremanezumab perform expect
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark
market capit less billion
capit billion
health index issuer
health index issuer market
inform includ limit price quot statist obtain sourc
believ reliabl repres accur complet reli
upon inform subject chang without notic provid inform purpos
regard offer sell solicit offer buy product
inform relat firm offic director employe proprietari account affili may
posit long short secur refer report and/or relat secur
time time may increas decreas posit express view contrari contain
report firm salespeopl trader profession may provid oral written market
commentari trade strategi contrari opinion express report firm proprietari
account may make invest decis inconsist opinion express report
past perform secur guarante predict futur perform transact strategi
describ herein may suitabl investor addit inform avail upon request
contact editori depart one feder street floor boston
like firm employe analyst receiv compens impact among factor overal firm
profit includ revenu among busi unit institut equiti invest
bank analyst howev compens specif invest bank servic transact
contribut firm invest bank activ
medacorp network healthcar profession attorney physician key opinion leader
specialist access leerink provid inform use analyst prepar research
statement valuat risk cover compani client refer http //
send request leerink partner llc editori
leerink partner llc make market compani plc teva pharmaceut ltd
leerink initi coverag april market perform rate
leerink place outperform rate teva march
member finra/sipc leerink partner llc right reserv document may reproduc
circul without written author
director equiti research
associ director research
director research geoffrey porg mbb
mid- small-cap biotechnolog
avenu america fl
